Soluprick Positive control
Sponsors
Dbv Technologies
Conditions
Peanut allergy
Phase 3
A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old Children with Peanut Allergy (VITESSE)
Active, not recruitingCTIS2022-502110-85-00
Start: 2024-01-18Target: 126Updated: 2025-12-15
A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy
RecruitingCTIS2025-521697-34-00
Start: 2025-12-01Target: 54Updated: 2026-01-21